Virginia and Texas Cannabis Legalization: Policy Status, Timeline & Market Impact

Executive Summary

Virginia and Texas have emerged as the next major battlegrounds for cannabis legalization in the United States, with both states advancing legislation that could unlock markets worth billions of dollars. Virginia's adult-use market is poised to launch after years of regulatory delays, while Texas lawmakers are considering comprehensive medical cannabis expansion and potential recreational frameworks. These developments represent a seismic shift in Southern cannabis policy, as two states with a combined population exceeding 38 million residents move toward regulated markets. Multi-state operators including Cresco Labs, Trulieve, and Green Thumb Industries have positioned themselves strategically through existing medical operations and real estate acquisitions. The outcomes in Virginia and Texas will likely influence cannabis policy across the Southeast and establish precedents for how conservative-leaning states structure their regulatory frameworks. With Virginia's market projected to generate $300-400 million in annual sales by year three and Texas potentially reaching $1.5 billion, the stakes for patients, operators, investors, and policymakers have never been higher.

Why These Markets Matter

Virginia and Texas together represent approximately 12% of the U.S. population and could add $2 billion in combined annual cannabis sales to the national market. Virginia's 8.6 million residents and Texas's 30 million residents create a massive addressable market for cannabis operators. Unlike smaller state markets that can be saturated quickly, these states offer sustained growth potential over multiple years. Virginia's adult-use market is expected to serve 15-20% of the adult population within the first three years, generating substantial tax revenue for state coffers while creating thousands of jobs in cultivation, processing, retail, and ancillary services. Texas presents an even larger opportunity despite its more conservative political landscape. The state's existing Compassionate Use Program serves fewer than 100,000 registered patients under highly restrictive conditions, leaving enormous unmet medical demand. Industry analysts project that a fully realized Texas medical program could serve 500,000-750,000 patients, with adult-use potentially reaching 2-3 million regular consumers. For patients, these policy changes mean expanded access to cannabis therapies for conditions including chronic pain, PTSD, cancer, epilepsy, and multiple sclerosis. Virginia's existing medical program serves approximately 60,000 registered patients, while advocates estimate that 200,000-300,000 Virginians could benefit from medical cannabis access. In Texas, veterans groups have been particularly vocal advocates, noting that more than 1.5 million veterans reside in Texas, many of whom could benefit from cannabis-based PTSD treatments. The business implications extend beyond cultivation and retail. Real estate investment trusts, security firms, testing laboratories, packaging companies, and software providers all stand to benefit. Virginia's Cannabis Control Authority estimates the adult-use market will create 11,000-13,000 direct jobs and generate $154 million in annual tax revenue once fully operational.

Background and History

Virginia and Texas have followed dramatically different paths toward cannabis reform, with Virginia moving incrementally from decriminalization to full legalization while Texas has maintained one of the nation's most restrictive medical programs.

Virginia's Journey: 2015-2026

Virginia's cannabis policy evolution began in earnest in 2015 when the General Assembly passed legislation allowing cannabidiol (CBD) oil for treatment-resistant epilepsy patients. This narrow medical program required physician certification and restricted THC content to no more than 5%. The law created no legal supply chain, forcing patients to obtain products from other states or illegal sources. In 2017, Virginia expanded its medical program through House Bill 2317, which established five vertically integrated pharmaceutical processors to cultivate, process, and dispense medical cannabis products. The Virginia Board of Pharmacy issued licenses to Columbia Care, Dharma Pharmaceuticals, gLeaf, Dalitso, and Dharma Pharmaceuticals in 2018, with the first dispensaries opening in 2020. The 2019 legislative session brought incremental decriminalization. House Bill 972 reduced simple possession of marijuana from a criminal misdemeanor to a civil violation punishable by a $25 fine for first offenses. This represented a significant shift in enforcement priorities, though possession remained illegal. The watershed moment came in April 2021 when Governor Ralph Northam signed House Bill 2312 and Senate Bill 1406, making Virginia the first Southern state to legalize adult-use cannabis. The legislation allowed adults 21 and older to possess up to one ounce of cannabis and cultivate up to four plants per household for personal use, effective July 1, 2021. However, the law delayed commercial sales until 2024, pending regulatory framework development. The 2021 legislation created the Virginia Cannabis Control Authority (CCA) as the regulatory body responsible for licensing and oversight. The law established a social equity framework prioritizing licenses for individuals from communities disproportionately impacted by cannabis prohibition, including those with prior cannabis convictions. Political changes complicated implementation. The November 2021 elections brought Republican Governor Glenn Youngkin into office alongside a Republican-controlled House of Delegates. Youngkin expressed opposition to commercial cannabis sales, creating regulatory uncertainty that delayed market launch from the original 2024 target. Throughout 2022 and 2023, the General Assembly debated various amendments to the commercial framework. Key disputes centered on license allocation, social equity provisions, tax rates, and local control provisions. The Democratic-controlled Senate pushed for broader social equity measures, while the Republican House sought tighter regulations and higher barriers to entry. In February 2024, a compromise framework emerged. House Bill 698 established a tiered licensing system with 450 total retail licenses allocated across Virginia's health districts, with 30% reserved for social equity applicants. The legislation set a 21% excise tax on retail sales, with revenue allocated to education, substance abuse treatment, and social equity programs. The CCA began accepting license applications in September 2024, with the first conditional licenses issued in March 2025. Retail sales commenced in select jurisdictions in January 2026, though many localities exercised their option to delay or prohibit commercial operations, creating a patchwork of access across the state.

Texas's Restrictive Path: 2015-2026

Texas has maintained one of the nation's most conservative cannabis policies despite growing public support for reform. The state's Compassionate Use Program, established by Senate Bill 339 in 2015, initially allowed low-THC cannabis (0.5% THC or less) only for intractable epilepsy patients. The 2019 legislative session brought modest expansion through House Bill 3703, which added terminal cancer, autism, multiple sclerosis, spasticity, amyotrophic lateral sclerosis (ALS), seizure disorders, and incurable neurodegenerative diseases to the qualifying conditions list. The law also increased the THC cap to 1%. House Bill 1535 in 2021 further expanded qualifying conditions to include PTSD and all forms of cancer, while raising the THC limit to 5%. As of August 2026, Texas has licensed only three vertically integrated dispensing organizations: Compassionate Cultivation, Cansortium Texas (operating as Surterra Wellness), and Goodblend Texas. The 2023 legislative session saw unprecedented cannabis reform proposals, though most failed to advance. House Bill 218, which would have created a comprehensive medical cannabis program with broader qualifying conditions and higher THC limits, passed the House but died in the Senate. House Bill 447, which would have decriminalized possession of up to one ounce, similarly failed to reach a Senate vote despite bipartisan House support. The current 2026 legislative session has brought renewed momentum. Senate Bill 711, filed by Senator José Menéndez (D-San Antonio), would expand qualifying conditions to include chronic pain, anxiety, depression, and insomnia while removing THC limits entirely. The bill has attracted 12 co-sponsors including three Republicans, signaling shifting political dynamics. House Bill 2312, filed by Representative Joe Moody (D-El Paso), goes further by establishing a framework for adult-use legalization. The bill would allow adults 21 and older to possess up to 2.5 ounces and cultivate six plants per person (12 per household). It proposes a 10% excise tax with revenue allocated to education and criminal justice reform. While passage remains uncertain, the bill has advanced further than any previous recreational proposal, clearing the House Criminal Jurisprudence Committee in July 2026.

Key Players

Virginia Cannabis Control Authority

The Virginia Cannabis Control Authority serves as the state's regulatory body for all commercial cannabis activity, wielding significant power over market structure and operator success. Created by the 2021 legalization statute, the CCA operates under the Virginia Secretary of Agriculture and Forestry. The five-member board includes appointees from the Governor, Senate, and House of Delegates. Chief Administrator Aaron Bowles has emphasized the agency's commitment to social equity while maintaining strict regulatory oversight. According to the CCA's 2025 annual report, the agency has issued 127 conditional retail licenses, 43 cultivation licenses, and 28 processing licenses as of June 2026. The CCA's seed-to-sale tracking system, powered by Metrc, monitors all commercial cannabis movement throughout the state.

Texas Department of State Health Services

The Texas Department of State Health Services (DSHS) administers the Compassionate Use Program through its Compassionate Use Registry. DSHS has faced criticism from patient advocates for restrictive interpretations of qualifying conditions and burdensome physician registration requirements. As of July 2026, only 847 physicians have registered to recommend medical cannabis, representing less than 2% of Texas's licensed physicians.

Multi-State Operators

Several major MSOs have positioned themselves for Virginia and Texas market entry through strategic investments and existing medical operations. Cresco Labs entered Virginia through its 2021 acquisition of Dharma Pharmaceuticals, one of the state's five original medical processors. The company operates cultivation facilities in Staunton and dispensaries in Bristol, Manassas, and Richmond. Cresco has announced plans to open 12 additional retail locations across Virginia by December 2026. Trulieve acquired Dharma Pharmaceuticals (a different entity from Cresco's acquisition) in 2022, gaining access to Virginia's medical market. The Florida-based MSO operates cultivation facilities in Danville and has opened eight dispensaries statewide. Trulieve CEO Kim Rivers said in a May 2026 earnings call that Virginia represents a "top-tier growth market" for the company. Green Thumb Industries does not currently hold Virginia licenses but has secured real estate options for cultivation and retail sites in anticipation of additional license rounds. The company operates in 15 states and has identified Virginia and Texas as strategic expansion priorities. Columbia Care, now part of Cresco Labs following their 2023 merger, previously operated as one of Virginia's original medical processors. The integration has created the state's largest vertically integrated operator by cultivation capacity. In Texas, the three licensed dispensing organizations remain privately held. Compassionate Cultivation, founded in 2017, operates the state's largest cultivation facility in Manchaca with approximately 40,000 square feet of canopy. Cansortium Texas (Surterra Wellness) operates facilities in the Dallas-Fort Worth area, while Goodblend Texas maintains operations in Houston.

Advocacy Organizations

Virginia NORML has been instrumental in advancing legalization efforts through grassroots organizing and legislative advocacy. Executive Director Jenn Michelle Pedini has testified before the General Assembly numerous times, emphasizing social equity and criminal justice reform priorities. Marijuana Policy Project provided strategic support for Virginia's 2021 legalization campaign and continues to monitor implementation. The organization has focused on ensuring localities do not create excessive barriers to commercial operations. In Texas, Texas NORML and Texans for Responsible Marijuana Policy have led reform efforts. These organizations have built coalitions including veterans groups, medical professionals, and criminal justice reform advocates. Ground Game Texas, a progressive organizing group, has made cannabis reform a priority issue in voter registration and turnout efforts.

Opposition

Smart Approaches to Marijuana (SAM) has actively opposed legalization in both states, arguing that commercial cannabis increases youth access and impaired driving. The organization has lobbied Virginia legislators to repeal the 2021 legalization law and has testified against Texas reform bills. Law enforcement organizations including the Virginia Association of Chiefs of Police and Texas Municipal Police Association have expressed concerns about impaired driving enforcement and workplace safety. These groups have not uniformly opposed medical expansion but have consistently opposed adult-use legalization.

Legal and Regulatory Framework

Virginia and Texas operate under fundamentally different legal structures, with Virginia having enacted comprehensive legalization while Texas maintains cannabis prohibition under the Texas Controlled Substances Act.

Virginia Law

Virginia Code § 4.1-600 through § 4.1-606 establishes the legal framework for adult-use cannabis. The statute allows adults 21 and older to possess up to one ounce of cannabis flower and cultivate up to four plants per household for personal use. Public consumption remains prohibited, with violations subject to civil penalties. Virginia Code § 4.1-1600 creates the licensing structure for commercial operations, establishing five license types: cultivation, manufacturing, retail, testing, and transportation. The law requires vertical integration for the first two years of commercial operations, meaning retailers must be affiliated with licensed cultivators. This provision sunsets in January 2028, after which independent retailers may source from multiple suppliers. The statute establishes a 21% excise tax on retail sales under Virginia Code § 4.1-1604, with revenue allocated as follows: 30% to K-12 education, 25% to substance abuse treatment and prevention, 20% to social equity programs, 15% to public health initiatives, and 10% to law enforcement training. Social equity provisions under Virginia Code § 4.1-1603 prioritize license applicants who have resided in economically disadvantaged areas for at least five years, have prior cannabis convictions, or are related to individuals with cannabis convictions. The law requires 30% of all licenses be reserved for social equity applicants and establishes a Cannabis Equity Reinvestment Fund to provide technical assistance and low-interest loans. Virginia's medical cannabis program operates under separate statutory authority in Virginia Code § 54.1-3408.3, which establishes the Board of Pharmacy's regulatory authority over pharmaceutical processors. Medical patients may possess up to a 90-day supply as determined by their certifying physician.

Texas Law

Cannabis remains a Schedule I controlled substance under the Texas Controlled Substances Act (Texas Health and Safety Code § 481.002). Possession of any amount is a criminal offense, with penalties ranging from Class B misdemeanor (up to 180 days in jail and $2,000 fine) for under two ounces to felony charges for larger amounts. The Compassionate Use Program operates under Texas Occupations Code § 169.001 as a narrow exception to prohibition. The statute allows physicians to recommend low-THC cannabis (defined as cannabis containing not more than 5% THC by weight) for patients with qualifying medical conditions. Texas Administrative Code Title 25, Part 1, Chapter 169 establishes the regulatory framework for dispensing organizations. The rules require vertical integration, with each licensed organization responsible for cultivation, processing, and dispensing. Dispensing organizations must maintain $5 million in surety bonds and comply with extensive security and tracking requirements. Texas law prohibits smoking or vaporizing medical cannabis products. Patients may only use tinctures, oils, capsules, or other non-inhalable forms. This restriction significantly limits product variety compared to other medical states. The pending Senate Bill 711 would amend Texas Occupations Code § 169.001 to remove THC limits and expand qualifying conditions. House Bill 2312 would create an entirely new regulatory chapter under Texas Health and Safety Code § 443, establishing adult-use legalization while maintaining cannabis as a controlled substance for purposes of federal law compliance.

Federal Law Interaction

Both Virginia and Texas programs operate in tension with federal prohibition under the Controlled Substances Act, 21 U.S.C. § 812, which classifies cannabis as a Schedule I substance. The Rohrabacher-Farr Amendment (now the Rohrabacher-Blumenauer Amendment), included in annual appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs. However, this protection does not extend to adult-use programs. The Cole Memorandum, rescinded in 2018 but still influential in DOJ enforcement priorities, established eight factors for federal prosecutors to consider when evaluating cannabis cases. These include preventing distribution to minors, preventing revenue from going to criminal enterprises, and preventing drugged driving. Virginia and Texas operators must structure their programs to address these federal concerns despite lack of explicit legal protection. Section 280E of the Internal Revenue Code, 26 U.S.C. § 280E, prohibits cannabis businesses from deducting ordinary business expenses for federal tax purposes, creating effective tax rates of 70-80% for many operators. This applies equally to Virginia and Texas cannabis businesses, significantly impacting profitability.

State-by-State Breakdown

Virginia

Virginia's adult-use market launched in January 2026 with limited retail availability, expanding gradually as localities approve commercial operations and the Cannabis Control Authority issues additional licenses. **Legal Status**: Adult-use legal; possession of up to one ounce and home cultivation of up to four plants permitted since July 2021; commercial sales authorized as of January 2026. **Possession Limits**: One ounce of flower or equivalent in concentrated or edible form for adults 21+; medical patients may possess up to a 90-day supply as determined by their physician. **Cultivation**: Adults may cultivate up to four plants per household for personal use; plants must be in a secure location not visible from public areas; commercial cultivation requires CCA licensing. **Retail Access**: As of August 2026, 89 retail dispensaries have opened across 34 localities; 52 localities have opted out of allowing commercial sales; 41 localities have imposed moratoriums pending further regulatory development. **Tax Structure**: 21% excise tax on retail sales plus standard 5.3% state sales tax; localities may impose additional taxes up to 3%. **Social Equity**: 30% of licenses reserved for social equity applicants; Cannabis Equity Reinvestment Fund provides $4.5 million annually in grants and loans; automatic expungement for prior simple possession convictions. **Medical Program**: Approximately 60,000 registered patients as of July 2026; qualifying conditions include cancer, glaucoma, HIV/AIDS, cachexia, seizures, PTSD, and any condition for which a practitioner determines cannabis would be beneficial; no registration fee for patients. **Key Dates**: July 1, 2021 (possession and home cultivation legalized); September 1, 2024 (license applications opened); March 15, 2025 (first conditional licenses issued); January 10, 2026 (first retail sales commenced).

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs with no legal adult-use access, though legislative momentum for reform has accelerated in 2026. **Legal Status**: Medical cannabis legal only through Compassionate Use Program; all other possession, cultivation, and distribution remains criminal; adult-use proposals pending in 2026 legislative session. **Possession Limits**: Medical patients may possess a 90-day supply as dispensed by licensed organizations; no specific weight limit established; non-patients face criminal penalties for any amount. **Cultivation**: All cultivation prohibited except by licensed dispensing organizations; no home cultivation permitted even for medical patients. **Retail Access**: Three licensed dispensing organizations operate 15 total dispensary locations statewide; Compassionate Cultivation operates six locations, Surterra Wellness operates five locations, Goodblend Texas operates four locations. **Tax Structure**: Standard 6.25% state sales tax applies to medical cannabis; no additional cannabis-specific taxes; pending adult-use legislation proposes 10% excise tax. **Social Equity**: No social equity provisions in current law; House Bill 2312 proposes 40% license reservation for social equity applicants if enacted. **Medical Program**: Approximately 85,000 registered patients as of June 2026; qualifying conditions include epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, incurable neurodegenerative disease, and PTSD; 847 registered physicians; no patient registration fee but physician certification required. **Key Dates**: June 1, 2015 (Compassionate Use Program established); June 14, 2019 (qualifying conditions expanded); June 18, 2021 (PTSD and all cancers added, THC limit raised to 5%); July 15, 2026 (House Bill 2312 passed House Criminal Jurisprudence Committee).

Market and Business Implications

Virginia's adult-use market is projected to reach $350-400 million in annual sales by 2028, while Texas's potential medical expansion could generate $800 million-$1.2 billion annually, with adult-use adding another $1.5-2 billion if legalized.

Virginia Market Dynamics

Virginia's phased rollout has created supply constraints that have benefited early-licensed operators. Average retail prices in Virginia's first six months ranged from $45-55 per eighth ounce for flower, approximately 20-30% higher than mature markets like Colorado or Oregon. These elevated prices reflect limited competition and high startup costs, including licensing fees, real estate, and regulatory compliance. The state's initial vertical integration requirement has concentrated market power among well-capitalized operators. Cresco Labs and Trulieve together control approximately 60% of Virginia's current retail capacity. This consolidation has raised concerns among social equity advocates who argue that smaller operators cannot compete effectively. Wholesale cannabis prices in Virginia averaged $2,800-3,200 per pound in the first quarter of 2026, significantly above the $800-1,200 per pound typical in mature markets. These prices should decline as cultivation capacity expands and the vertical integration requirement sunsets in 2028. Virginia's medical program has seen patient enrollment increase 40% since adult-use sales commenced, contrary to predictions that recreational access would cannibalize medical demand. This growth reflects the medical program's advantages: lower taxes (medical sales are exempt from the 21% excise tax), higher possession limits, and workplace protections for registered patients.

Texas Market Potential

Texas represents the largest untapped cannabis market in the United States. Industry analysts at Brightfield Group project that a fully realized Texas medical program could generate $800 million-$1.2 billion in annual sales, while adult-use legalization could create a $2-3 billion market within five years. The state's current Compassionate Use Program generates an estimated $45-60 million in annual sales across three operators, suggesting significant unmet demand. Patient enrollment has grown 180% since 2021 despite restrictive qualifying conditions and limited physician participation. If Senate Bill 711 passes, expanding qualifying conditions and removing THC limits, analysts project patient enrollment could reach 400,000-600,000 within three years. At an average annual patient spend of $1,800-2,400, this would generate $720 million-$1.44 billion in sales. Adult-use legalization through House Bill 2312 would create even larger opportunities. Texas's 21.7 million adults represent a potential customer base larger than the entire population of most states. Assuming 15-18% adult participation rates typical of mature markets, Texas could have 3.2-3.9 million regular cannabis consumers.

Multi-State Operator Strategies

MSOs are positioning for Texas entry through multiple strategies. Cresco Labs has secured real estate options in Houston, Dallas, Austin, and San Antonio totaling approximately 250,000 square feet of potential cultivation space. The company's existing Virginia operations provide a blueprint for navigating Southern market dynamics. Trulieve has focused on building brand recognition through educational initiatives and strategic partnerships with patient advocacy groups. The company has committed $8 million to Texas market entry preparations, according to its Q2 2026 earnings report. Curaleaf has taken a different approach, acquiring a Texas-based hemp company with cultivation infrastructure that could be converted to cannabis production if legalization occurs. This strategy reduces startup timelines and capital requirements compared to building facilities from scratch. Smaller operators face significant challenges. Texas's proposed licensing framework includes $500,000 application fees and $2 million performance bonds, creating high barriers to entry. Virginia's experience suggests that well-capitalized MSOs will dominate initial market share, with independent operators gaining traction only after vertical integration requirements sunset.

Ancillary Business Opportunities

Cannabis legalization creates opportunities beyond plant-touching businesses. Security firms, testing laboratories, and compliance software providers all benefit from new market openings. Metrc, the dominant seed-to-sale tracking provider, has secured contracts in Virginia and is positioned to win Texas contracts if legalization advances. The company's track-and-trace systems are required in most state markets, creating recurring revenue streams. Real estate investment trusts (REITs) including Innovative Industrial Properties have acquired cultivation facilities in Virginia, providing sale-leaseback financing for operators. IIP's Virginia portfolio includes four properties totaling 385,000 square feet with $94 million in invested capital as of June 2026. Testing laboratories represent another high-margin opportunity. Virginia requires all cannabis products undergo testing for potency, pesticides, heavy metals, and microbial contaminants. The state has licensed 12 testing facilities, each processing an average of 800-1,200 samples monthly at fees of $300-600 per sample.

What Experts Say

Industry analysts, policy experts, and market participants offer divergent perspectives on the Virginia and Texas cannabis markets, with consensus that both states represent significant opportunities despite regulatory uncertainties. According to Brightfield Group's managing director Brendan Mitchel-Chesebro, Virginia's phased rollout has created artificial scarcity that benefits early operators but may slow overall market development. The firm's August 2026 market report notes that Virginia's per-capita cannabis sales trail other adult-use states by 30-40%, suggesting either supply constraints or regulatory barriers are limiting market growth. Marijuana Policy Project's Virginia director Pedini has emphasized that local opt-outs represent the most significant barrier to market access. In testimony before the Virginia General Assembly in March 2026, she noted that 52 localities prohibiting commercial sales represent approximately 2.1 million residents, or 24% of Virginia's population, without legal access to adult-use retail. Texas NORML's executive director Jax Finkel said in a July 2026 interview with the Texas Tribune that House Bill 2312's advancement through committee represents a "watershed moment" for Texas cannabis policy. Finkel noted that three Republican committee members voting in favor signals shifting political dynamics, though passage remains uncertain given Lieutenant Governor Dan Patrick's historical opposition to cannabis reform. Financial analysts at Cowen & Company have identified Cresco Labs and Trulieve as best-positioned to capitalize on Virginia and Texas opportunities. In an August 2026 research note, analyst Vivien Azer wrote that both companies have "demonstrated operational excellence in limited-license markets" and possess the capital resources to scale rapidly as regulations permit. Viridian Capital Advisors president Harrison Phillips projects that Virginia will issue an additional 200-300 retail licenses by 2028, creating opportunities for smaller operators and social equity applicants. However, Phillips cautioned that capital access remains a significant challenge for undercapitalized applicants, with traditional banking largely unavailable due to federal prohibition. Cannabis industry attorney Hilary Bricken, partner at Harris Bricken, has noted that Virginia's regulatory framework includes several provisions that could trigger legal challenges. In a May 2026 blog post, Bricken identified the vertical integration requirement and social equity license reservations as potential targets for litigation, though she assessed both as likely to withstand scrutiny based on precedent from other states. Texas Medical Association president Dr. Rick Snyder has expressed support for expanded medical access while opposing adult-use legalization. In testimony before the Texas Senate Health and Human Services Committee in June 2026, Snyder said the association supports removing THC limits and expanding qualifying conditions but believes recreational use should remain prohibited pending additional research on long-term health effects.

What's Next

Virginia's market will expand significantly through 2027 as additional licenses are issued and localities reconsider opt-out decisions, while Texas faces critical legislative decisions in the current 2026 session that will determine whether meaningful reform advances.

Virginia Timeline

**September 2026**: Virginia Cannabis Control Authority will announce the second round of license applications, with approximately 150 additional retail licenses, 30 cultivation licenses, and 20 processing licenses available. Applications will be accepted through November 2026. **January 2027**: The CCA will begin issuing conditional licenses from the second application round. Successful applicants typically require 6-12 months to become operational, suggesting new retail locations will open throughout 2027. **July 2027**: The Virginia General Assembly will reconvene for its 2027 session, with cannabis policy likely to be a significant agenda item. Potential amendments include adjusting tax rates, modifying social equity provisions, and addressing local opt-out authority. **January 2028**: Virginia's vertical integration requirement sunsets, allowing independent retailers to source products from multiple cultivators and processors. This change is expected to increase competition and reduce wholesale prices.

Texas Timeline

**August 2026**: The Texas House of Representatives will vote on House Bill 2312, the adult-use legalization proposal. Passage requires 76 votes in the 150-member chamber. If approved, the bill moves to the Senate, where Lieutenant Governor Patrick controls the legislative calendar. **September-October 2026**: The Texas Senate will consider Senate Bill 711 (medical expansion) and potentially House Bill 2312 if it passes the House. Patrick has historically blocked cannabis reform bills from receiving Senate votes, though growing public support and bipartisan House passage could create political pressure. **November 2026**: If either bill passes both chambers, Governor Greg Abbott will have 10 days to sign, veto, or allow the bill to become law without signature. Abbott has not publicly stated his position on the current proposals. **January 2027**: If legislation passes in 2026, the Texas Department of State Health Services would begin rulemaking for medical expansion or the newly created Texas Cannabis Commission would begin developing adult-use regulations. This process typically requires 12-18 months before license applications open. **2028-2029**: If adult-use legalization passes, the first retail sales would likely commence 24-30 months after enactment, based on timelines in other states. Medical expansion could occur more quickly, potentially within 12-18 months, since infrastructure already exists.

Federal Developments

The Drug Enforcement Administration's ongoing review of cannabis scheduling could impact both states. The DEA published a Notice of Proposed Rulemaking in May 2024 proposing to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. If finalized, this change would eliminate Section 280E tax penalties for cannabis businesses, significantly improving operator profitability. The rescheduling process includes a public comment period that closed in July 2024, followed by administrative law judge hearings scheduled for late 2026. A final rule is not expected until 2027 at the earliest, with potential legal challenges likely to extend the timeline further. Congressional legislation including the SAFER Banking Act, which would provide cannabis businesses access to traditional banking services, remains stalled despite bipartisan support. Passage would significantly reduce operational costs and improve safety by reducing cash-intensive operations.

Further Reading

• Virginia Cannabis Control Authority Official Website: https://www.cca.virginia.gov
• Texas Department of State Health Services Compassionate Use Program: https://www.dshs.texas.gov/texas-compassionate-use-program
• Virginia Code Title 4.1, Chapter 16 (Cannabis Control Act): https://law.lis.virginia.gov/vacode/title4.1/chapter16/
• Texas Occupations Code Chapter 169 (Compassionate Use): https://statutes.capitol.texas.gov/Docs/OC/htm/OC.169.htm
• Virginia General Assembly Legislative Information System: https://lis.virginia.gov
• Texas Legislature Online: https://capitol.texas.gov
• Marijuana Policy Project State Policy Reports: https://www.mpp.org/states/
• NORML Virginia: https://www.vanorml.org
• Texas NORML: https://www.texasnorml.org
• Brightfield Group Cannabis Market Research: https://www.brightfieldgroup.com
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (Federal Register Vol. 89, No. 97): https://www.federalregister.gov/documents/2024/05/21/2024-10974/schedules-of-controlled-substances-rescheduling-of